Melatonin Use in Children Raises Safety Concerns

This article originally appeared here.
Share this content:
Melatonin Use in Children Raises Safety Concerns
Melatonin Use in Children Raises Safety Concerns

WEDNESDAY, March 11, 2015 (HealthDay News) -- Considerable safety concerns surround use of melatonin for children with sleep disorders, according to a review article published online Feb. 3 in the Journal of Paediatrics and Child Health.

David J. Kennaway, Ph.D., from the University of Adelaide in Australia, examined safety issues associated with prescription of melatonin for children with sleep disorders.

Kennaway notes that because melatonin is considered a dietary supplement and not a drug, it has not been evaluated for safety in any population group. No appropriate studies have demonstrated the safety of melatonin in children or adults. Apart from use in patients over 55 years with primary sleep disorder, all other uses of melatonin are off-label. Research in animal models (rodents, sheep, and primates) has shown that melatonin can have significant effects on the reproductive organs; long-term endocrine effects have not been assessed in children and adolescents. Furthermore, there is potential for interactions with drugs prescribed to children for sleep disorders.

"Prescription of melatonin to any child whether severely physically or neurologically disabled or developing normally should be considered only after the biochemical diagnosis of an underlying sleep timing abnormality and after full disclosure to the carers of information about the known actions of melatonin on reproductive and other systems in animal models and the disclosure that there is a lack of appropriate studies conducted in children," Kennaway writes.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths